Pharma Marketing Blog represents the opinions of
John Mack
Publisher of
Pharma Marketing News.
We accept advertising relevant to the interests of our members.
For more information, see:
Operated by:
VirSci Corporation
PO Box 760
Newtown, PA 18940
215-504-4164
215-504-5739 (FAX)
E-mail: infovirsci@virsci.com
My Humble Opinion
|
Other People's Opinion
|
| A "Must Read" Blog for Insiders. -- Wall Street Journal | A bi-weekly podcast. Listen and call-in live online or download to your iPod! |
| Also see Pharma Marketing News OpEd Pieces |
Lilly Cuts PAP and Runs from Patients in Need, Putting Profits FirstPosted: April 22, 2007Lilly dropped its Prescription Assistance Program (PAP) for the poor as of December 31, 2006. At least one Wall Street analyst -- Merrill Lynch's David Risinger -- points out that Lilly's bottom line is benefiting significantly from this action: "Many prescriptions were transitioned to Medicare Part D and other funding sources, which compensate Lilly at a dramatically higher level for prescriptions. Hence, Lilly is realizing a significant net price benefit in 2007 (vs. 2006) for a number of products (in particular Forteo)." Risinger implies that Lilly had no choice but to drop its PAP due to Medicare Part D rule. But there a way around Medicare's anti-kickback statute for pharma companies that truly wish to continue their patient assistance programs. Lilly simply chose not to take advance of it. For more on this, see today's post to Pharma Marketing Blog. For more posts in related topic areas, see: If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe.
|
Special Supplement Physician Education Key Opinion Leaders, Medical Science Liaisons, & CME
It's a new era for pharmaceutical company support of physician education. New guidelines and regulations from various governmental and non-governmental regulatory bodies have come into play during the past few years. The second event defining this new era was the withdrawal of Vioxx from the market in 2004 and the subsequent re-emergence of the importance of physicians as "learned intermediaries."
More than ever, it is important to educate physicians about new drugs and to keep this education separate from the marketing function of the company yet aligned with commercial goals. This Special Supplement to Pharma Markeing News is critical reading for pharmaceutical companies and physician education service providers wishing to understand the new roles of key opinion leader physicians (KOLs) and medical science liaisons (MSLs) in the physician education process. Order and pay for this Special Supplement now using your credit card ONLY $29.95
If you wish to pay by check or credit card off-line, please use:
|